Table 3 Results of sensitivity analyses
Treatment | Total costs | Life years | QALYs | Incremental costs | Incremental life years | Incremental QALYs | Cost per life year gained | Cost per QALY gained |
|---|---|---|---|---|---|---|---|---|
Base case results | ||||||||
Best supportive care | £4756 | 0.877 | 0.469 | – | – | – | – | – |
Ofatumumab | £43,942 | 1.494 | 0.770 | £39,186 | 0.617 | 0.301 | £63,542 | £130,563 |
Sensitivity analysis: utility values set to ‘following first-line treatment’ (progression-free survival 0.777 & post-progression 0.540) | ||||||||
Best supportive care | £4756 | 0.877 | 0.551 | – | – | – | – | – |
Ofatumumab | £43,942 | 1.494 | 0.770 | £39,186 | 0.617 | 0.219 | £63,542 | £112,067 |
Sensitivity analysis: utility values set to ‘following final treatment’ (progression-free survival 0.428 & post-progression 0.279) | ||||||||
Best supportive care | £4756 | 0.877 | 0.294 | – | – | – | – | – |
Ofatumumab | £43,942 | 1.494 | 0.770 | £39,186 | 0.617 | 0.476 | £63,542 | £211,918 |
Sensitivity analysis: independent curve fit used for control arm | ||||||||
Best supportive care | £4884 | 0.952 | 0.497 | – | – | – | – | – |
Ofatumumab | £43,942 | 1.494 | 0.770 | £39,058 | 0.542 | 0.273 | £72,080 | £143,402 |
Sensitivity analysis: alternative Cox regression including 17p and 11q chromosomal deletions | ||||||||
Best supportive care | £4876 | 0.945 | 0.501 | – | – | – | – | – |
Ofatumumab | £43,942 | 1.494 | 0.770 | £39,066 | 0.550 | 0.269 | £71,076 | £145,524 |
Sensitivity analysis: hazard rate on best supportive care increased by 20% | ||||||||
Best supportive care | £4524 | 0.748 | 0.405 | – | – | – | – | – |
Ofatumumab | £43,942 | 1.494 | 0.770 | £39,419 | 0.746 | 0.365 | £52,837 | £108,205 |
Sensitivity analysis: ofatumumab administration time doubled | ||||||||
Best supportive care | £4756 | 0.945 | 0.405 | – | – | – | – | – |
Ofatumumab | £45,694 | 1.494 | 0.770 | £40,938 | 0.617 | 0.301 | £66,383 | £136,399 |